Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF DILUTIVE COMMON STOCK EQUIVALENTS (Details)

v3.21.2
SCHEDULE OF DILUTIVE COMMON STOCK EQUIVALENTS (Details) - shares
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 3,384,984 1,161,020
Convertible Notes Payable [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total [1] 1,152,411
Stock Options [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 854,892 7,809
Stock Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 2,530,092 800
[1] There were 0 and 1,152,411 shares of our common stock issuable upon conversion of $1,152,411 of Convertible Notes Payable at a conversion rate of $1.00 per share, as of September 30, 2021 and 2020, not accounting for 9.99% beneficial ownership limitation.